No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BOLT Bolt Biotherapeutics
- 1.330
- +0.070+5.56%
Close May 13 16:00 ET
- 1.310
- -0.020-1.50%
Post 19:43 ET
50.71MMarket Cap-726P/E (TTM)
1.335High1.190Low206.70KVolume1.270Open1.260Pre Close264.21KTurnover0.98%Turnover RatioLossP/E (Static)38.13MShares2.03052wk High0.45P/B28.14MFloat Cap0.84052wk Low--Dividend TTM21.16MShs Float43.070Historical High--Div YieldTTM11.51%Amplitude0.840Historical Low1.278Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. Kineta (NASDAQ:KA) shares rose 8.46% to
Bolt Biotherapeutics: A Strong Buy on Clinical Progress and Financial Stability
Bolt Biotherapeutics' Promising Trajectory in Immuno-Oncology: A Strong Buy Recommendation
Express News | HC Wainwright & Co. Maintains Buy on Bolt Biotherapeutics, Maintains $8 Price Target
Bolt Biotherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 583.76% HC Wainwright & Co. $8 → $8 Maintains Buy 08/08/2023 583.76% HC Wainwright & Co. → $8 R
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Intuitive Surgical (ISRG) and Bolt Biotherapeutics (BOLT)
Comments
$Bolt Biotherapeutics(BOLT.US$ Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu® 2 MINUTES AGO, 7:00 AM EST VIA GLOBENEWSWIRE![]()
1
1
$Bolt Biotherapeutics(BOLT.US$ Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 25.86 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $2.53 million which beat the analyst consensus estimate of $1.72 million by 46.98 percent. This is a 19.70 percent increase over sales of $2.11 million the same perio...
$Bolt Biotherapeutics(BOLT.US$ Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023![]()
$Bolt Biotherapeutics(BOLT.US$ Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers![]()
$Bolt Biotherapeutics(BOLT.US$
It has healthy balance sheet (25% debt) and income, believe it's under value with $1 now...
It has healthy balance sheet (25% debt) and income, believe it's under value with $1 now...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Massinooo : I’m in with a little position